Cargando…
SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410582/ https://www.ncbi.nlm.nih.gov/pubmed/34002025 http://dx.doi.org/10.1038/s41375-021-01273-7 |
| _version_ | 1783747143386791936 |
|---|---|
| author | van der Werf, Inge Wojtuszkiewicz, Anna Yao, Huilan Sciarrillo, Rocco Meggendorfer, Manja Hutter, Stephan Walter, Wencke Janssen, Jeroen Kern, Wolfgang Haferlach, Claudia Haferlach, Torsten Jansen, Gerrit Kaspers, Gertjan J. L. Groen, Richard Ossenkoppele, Gert Cloos, Jacqueline |
| author_facet | van der Werf, Inge Wojtuszkiewicz, Anna Yao, Huilan Sciarrillo, Rocco Meggendorfer, Manja Hutter, Stephan Walter, Wencke Janssen, Jeroen Kern, Wolfgang Haferlach, Claudia Haferlach, Torsten Jansen, Gerrit Kaspers, Gertjan J. L. Groen, Richard Ossenkoppele, Gert Cloos, Jacqueline |
| author_sort | van der Werf, Inge |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8410582 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84105822021-09-22 SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia van der Werf, Inge Wojtuszkiewicz, Anna Yao, Huilan Sciarrillo, Rocco Meggendorfer, Manja Hutter, Stephan Walter, Wencke Janssen, Jeroen Kern, Wolfgang Haferlach, Claudia Haferlach, Torsten Jansen, Gerrit Kaspers, Gertjan J. L. Groen, Richard Ossenkoppele, Gert Cloos, Jacqueline Leukemia Letter Nature Publishing Group UK 2021-05-17 2021 /pmc/articles/PMC8410582/ /pubmed/34002025 http://dx.doi.org/10.1038/s41375-021-01273-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter van der Werf, Inge Wojtuszkiewicz, Anna Yao, Huilan Sciarrillo, Rocco Meggendorfer, Manja Hutter, Stephan Walter, Wencke Janssen, Jeroen Kern, Wolfgang Haferlach, Claudia Haferlach, Torsten Jansen, Gerrit Kaspers, Gertjan J. L. Groen, Richard Ossenkoppele, Gert Cloos, Jacqueline SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia |
| title | SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia |
| title_full | SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia |
| title_fullStr | SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia |
| title_full_unstemmed | SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia |
| title_short | SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia |
| title_sort | sf3b1 as therapeutic target in flt3/itd positive acute myeloid leukemia |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410582/ https://www.ncbi.nlm.nih.gov/pubmed/34002025 http://dx.doi.org/10.1038/s41375-021-01273-7 |
| work_keys_str_mv | AT vanderwerfinge sf3b1astherapeutictargetinflt3itdpositiveacutemyeloidleukemia AT wojtuszkiewiczanna sf3b1astherapeutictargetinflt3itdpositiveacutemyeloidleukemia AT yaohuilan sf3b1astherapeutictargetinflt3itdpositiveacutemyeloidleukemia AT sciarrillorocco sf3b1astherapeutictargetinflt3itdpositiveacutemyeloidleukemia AT meggendorfermanja sf3b1astherapeutictargetinflt3itdpositiveacutemyeloidleukemia AT hutterstephan sf3b1astherapeutictargetinflt3itdpositiveacutemyeloidleukemia AT walterwencke sf3b1astherapeutictargetinflt3itdpositiveacutemyeloidleukemia AT janssenjeroen sf3b1astherapeutictargetinflt3itdpositiveacutemyeloidleukemia AT kernwolfgang sf3b1astherapeutictargetinflt3itdpositiveacutemyeloidleukemia AT haferlachclaudia sf3b1astherapeutictargetinflt3itdpositiveacutemyeloidleukemia AT haferlachtorsten sf3b1astherapeutictargetinflt3itdpositiveacutemyeloidleukemia AT jansengerrit sf3b1astherapeutictargetinflt3itdpositiveacutemyeloidleukemia AT kaspersgertjanjl sf3b1astherapeutictargetinflt3itdpositiveacutemyeloidleukemia AT groenrichard sf3b1astherapeutictargetinflt3itdpositiveacutemyeloidleukemia AT ossenkoppelegert sf3b1astherapeutictargetinflt3itdpositiveacutemyeloidleukemia AT cloosjacqueline sf3b1astherapeutictargetinflt3itdpositiveacutemyeloidleukemia |